Category: Screening and Testing

Early detection is key to surviving world’s deadliest cancer

Without the CT test that you recommended, I would never have suspected I had lung cancer.

I am one of the lucky few cured of lung cancer, a rare outcome for patients diagnosed with the leading cause of cancer deaths annually… Read More

Posted by ALCF Staff on September 5th, 2018

ATS Conference May 2018

At the ATS (American Thoracic Society) was held in San Diego the end of May. While referrals to Low Dose CT (LDCT) screening still remains very low, much discussion occurred around screening and are those who are appropriate being referred. Topics ranged from should physicians and patients adhere to the National Lung Screening Trial (NLST)… Read More

Posted by ALCF Staff on June 29th, 2018

Lung Cancer Early Detection Challenge: Concept to Clinic

Looking for data scientists, software engineers, designers and researchers to build an open source software application that puts advances from machine learning into the hands of practicing clinicians. In addition to creating cutting-edge clinical software that helps detect lung cancer early, top contributors are eligible for a share of $100,000 in prize money. Click here… Read More

Posted by ALCF Staff on August 10th, 2017

Lung Cancer Updates from 2017 ASCO Annual Meeting

Each year in early June the American Society for Clinical Oncology holds its Annual Meeting (called simply “ASCO”) in Chicago. The theme for the 2017 meeting was “Making a Difference in Cancer Care WITH YOU.” Over 39,000 cancer researchers, clinicians, patient advocates, and industry representatives from around the world gathered to discuss the latest scientific… Read More

Posted by Janet Freeman-Daily on July 26th, 2017

ALCMI and Biocept Announce a Landmark Liquid Biopsy Clinical Trial

The Addario Lung Cancer Medical Institute (ALCMI) and Biocept, Inc., a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients, announce a clinical collaboration and initiation of the landmark ALCMI-009 liquid biopsy clinical trial, which was developed and will be conducted by ALCMI and its consortium of… Read More

Posted by ALCF Staff on May 10th, 2017

Do you know a ROS1-fusion positive cancer patient?

In May, 2016, the Bonnie J. Addario Lung Cancer Foundation launched the Global ROS1 Initiative, in partnership with cancer patients whose tumors are driven by ROS1 gene fusions. These ROS1 gene fusions are abnormal changes in cells that drive the growth and spread of several different cancer types such as non-small cell lung, gastric, ovarian,… Read More

Posted by Dr. Guneet Walia on February 23rd, 2017

Liquid Biopsy Test Approved by the FDA for EGFR+ Lung Cancer

On June 1, 2016 the US Food and Drug Administration (FDA) approved the first ever blood test to aid clinical decision making for targeted therapies for lung cancer. This blood test, a companion diagnostic called Cobas EGFR Mutation Test v2, allows the detection of mutations in the EGFR (Epidermal Growth Factor Receptor) gene, such as… Read More

Posted by Dr. Guneet Walia on September 29th, 2016

Lung Cancer Updates from ASCO 2016

Download PDF of this post What is ASCO? ASCO is the American Society of Clinical Oncology that has an annual meeting each year where key research and clinical medicine highlights are presented by cancer researchers & clinicians to the global community. This was the 52nd Annual Meeting of the American Society of Clinical Oncology, held… Read More

Posted by Dr. Guneet Walia on July 20th, 2016

New Clinical Trial Available for ALK+ NSCLC patients- XALT2

If you have non-small cell lung cancer (NSCLC), you may be interested in learning more about a clinical research study opportunity. Non-small cell lung cancer (NSCLC) is one of two types of lung cancer (the other is small cell lung cancer). Most lung cancers are NSCLC. Of the people who have NSCLC, only 3 percent… Read More

Posted by Danielle Hicks on April 1st, 2016

New Clinical Trial For Patients No Longer Benefitting from Standard Therapy, or For Whom No Standard Therapy is Available

This Monday, the American Society of Clinical Oncology (ASCO) launched its first ever clinical trial that has been designed with a unique format and allows patients with advanced solid tumor (including lung cancer), multiple myeloma, or B cell non-Hodgkin lymphoma who are no longer benefitting from standard anti-cancer treatments, or for whom no acceptable standard… Read More

Posted by Dr. Guneet Walia on March 23rd, 2016